2025-00213NoticeWallet

FDA Wants Surgeons to Use Glow-in-the-Dark Tumor Highlighters

Published Date: 1/8/2025

Notice

Summary

The FDA just dropped a draft guide to help drug makers create medicines that work with special optical imaging devices during surgeries. This guide is for companies developing drugs that help spot tumors or highlight body parts in real-time. If you’re in the biz, get your feedback in by April 8, 2025, so the FDA can shape the final rules—this could speed up approvals and save money down the road!

Analyzed Economic Effects

2 provisions identified: 2 benefits, 0 costs, 0 mixed.

Optical imaging may improve surgeries

If you have surgery to remove tumors or need delicate anatomical repairs, FDA says drugs used with optical imaging devices can help surgeons see tumors and normal structures more clearly. The guidance explains these imaging drugs can increase the likelihood of a safe and complete removal of cancers and can minimize the risk of unintended injury to normal anatomical structures.

Draft trial guidance for drug sponsors

The FDA published a draft guidance called "Developing Drugs for Optical Imaging" that gives recommendations to sponsors about clinical trial design to support development and approval of optical imaging drugs used during surgery. Sponsors and other stakeholders may submit comments on the draft guidance by April 8, 2025 via https://www.regulations.gov or by written/paper submission.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
1/8/2025

Department and Agencies

Department
Independent Agency
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register